Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD
Sign Up to like & getrecommendations! Published in 2020 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2019.12.006
Abstract: Introduction Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and… read more here.
Keywords: associated membranous; patients phospholipase; treatment; membranous nephropathy ... See more keywords